ijms-logo

Journal Browser

Journal Browser

New Research on Anti-Inflammatory Molecules in Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 463

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy
Interests: sex differences in inflammatory diseases and implications for sex-related therapy; pathobiochemistry of inflammation; molecular and biochemical pharmacology of natural and synthetic anti-inflammatory molecules
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, University of Naples Federico II, 80138 Naples, Italy
Interests: airway function; inflammatory lung diseases; sphingolipid metabolism; lipid mediators
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammatory diseases are the most common acute and chronic health conditions in the world. They are characterized by a very complex pathophysiological process, involving a myriad of enzymes, mediators, and receptors, producing proinflammatory and anti-inflammatory molecules. Despite the fact that the discovery of anti-inflammatory drugs has been very extensive, inflammatory diseases remain among the most serious health burdens, and the medical need for more potent and safe anti-inflammatory drugs still remains.

The topics covered will include (but are not limited to) the following:

  • The individuation of new targets for anti-inflammatory therapy;
  • Natural products as novel therapeutic strategies in inflammatory diseases;
  • New synthetic compounds with anti-inflammatory proprieties.

Prof. Dr. Antonietta Rossi
Prof. Dr. Fiorentina Roviezzo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

inflammation

anti-inflammatory molecules

natural products

lipid mediators

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2096 KiB  
Article
Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in Early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry
by Katarzyna Waligóra-Dziwak, Aleksandra Dańczak-Pazdrowska and Dorota Jenerowicz
Int. J. Mol. Sci. 2025, 26(9), 4230; https://doi.org/10.3390/ijms26094230 - 29 Apr 2025
Viewed by 122
Abstract
While clinical trials have shown the efficacy of using dupilumab and upadacitinib to treat atopic dermatitis (AD), long-term real-world data remain limited. This retrospective cohort study, utilizing data from the Polish National Health Fund Registry, evaluates the long-term effectiveness of dupilumab versus upadacitinib [...] Read more.
While clinical trials have shown the efficacy of using dupilumab and upadacitinib to treat atopic dermatitis (AD), long-term real-world data remain limited. This retrospective cohort study, utilizing data from the Polish National Health Fund Registry, evaluates the long-term effectiveness of dupilumab versus upadacitinib in early treatment responders, focusing on sustained efficacy outcomes and high levels of skin clearance. Data from the Polish National Health Fund Registry were analyzed for 435 patients; 220 were treated with dupilumab and 215 were treated with upadacitinib, each receiving treatment for at least 40 weeks. Upadacitinib had a faster onset of action, leading to significantly higher rates of complete skin clearance compared to dupilumab at weeks 16 and 28 (EASI100 at week 16: 19.5% vs. 7.3%, p < 0.001; week 28: 26.5% vs. 12.7%, p < 0.001). Dupilumab showed continuous efficacy gains, ultimately demonstrating superiority in achieving EASI75 and EASI90 at week 40, though no significant difference was observed in achieving EASI100. Both treatments provided sustained dermatological improvement and enhanced quality of life, achieving high levels of skin clearance over the long term. Full article
(This article belongs to the Special Issue New Research on Anti-Inflammatory Molecules in Diseases)
Show Figures

Figure 1

Back to TopTop